Y-Mabs Therapeutics Inc’s recently made public that its CHIEF BUSINESS OFFICER Gad Thomas unloaded Company’s shares for reported $0.42 million on Jun 11 ’24. In the deal valued at $12.00 per share,35,000 shares were sold. As a result of this transaction, Gad Thomas now holds 162,681 shares worth roughly $1.62 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Gad Thomas sold 35,000 shares, generating $421,050 in total proceeds. Upon selling the shares at $12.03, the CHIEF BUSINESS OFFICER now owns 197,681 shares.
Before that, Ber Gerard sold 722 shares. Y-Mabs Therapeutics Inc shares valued at $8,664 were divested by the Director at a price of $12.00 per share. As a result of the transaction, Ber Gerard now holds 1,608 shares, worth roughly $15999.599999999999.
Truist initiated its Y-Mabs Therapeutics Inc [YMAB] rating to a Buy in a research note published on June 28, 2024; the price target was $21. A number of analysts have revised their coverage, including Wedbush’s analysts, who increased its forecast for the stock in early May from “a Neutral” to “an Outperform”. Guggenheim also remained covering YMAB and has decreased its forecast on April 03, 2023 with a “Neutral” recommendation from previously “Buy” rating. Morgan Stanley revised its rating on January 27, 2023. It rated YMAB as “an Underweight” which previously was an “an Equal-weight”.
Price Performance Review of YMAB
On Monday, Y-Mabs Therapeutics Inc [NASDAQ:YMAB] saw its stock fall -11.24% to $9.95. Over the last five days, the stock has lost -7.53%. Y-Mabs Therapeutics Inc shares have risen nearly 45.89% since the year began. Nevertheless, the stocks have risen 61.53% over the past one year. While a 52-week high of $20.90 was reached on 03/01/24, a 52-week low of $4.60 was recorded on 01/03/24. SMA at 50 days reached $11.90, while 200 days put it at $11.50.
Levels Of Support And Resistance For YMAB Stock
The 24-hour chart illustrates a support level at 8.74, which if violated will result in even more drops to 7.54. On the upside, there is a resistance level at 10.82. A further resistance level may holdings at 11.70. The Relative Strength Index (RSI) on the 14-day chart is 33.14, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.74, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 65.08%. Stochastics%K at 34.57% indicates the stock is a holding.
How much short interest is there in Y-Mabs Therapeutics Inc?
A steep rise in short interest was recorded in Y-Mabs Therapeutics Inc stocks on
